-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

Benzinga·08/13/2026 13:58:11
Listen to the news
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.